Novartis to acquire Avidity Biosciences for about $12B

Source: New York Post Business | Published: October 26, 2025, 7:46 pm | Read Original

Neutral 0.0

Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.

Read Source Login to use Pulse AI

Pulse AI Analysis

Pulse analysis not available yet. Click "Get Pulse" above.

This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.

More Like This

Glideslope AI

Novartis to acquire Avidity Biosciences for about $12B

Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.

New York Post Business • Oct 26, 2025 • Found on Glideslope.ai

Post hash: g4nv4kt • glideslope.ai/post/g4nv4kt

Sentiment

Neutral • Score: 0.0

-100 (Bearish) +100 (Bullish)

Fraywire Market Portal, Breaking Metrics Newsletter, and Glideslope AI are designed for informational purposes only. The content provided across these platforms—including, but not limited to, stock and crypto watchlists, price tracking, trade tracking, sentiment analysis, and news articles—should not be construed as financial advice or research reports. Users are encouraged to conduct their own research and consult with qualified financial professionals before making any investment decisions. While we strive to ensure the accuracy, completeness, and reliability of the information provided, Fraywire, Breaking Metrics, and Glideslope AI make no guarantees or warranties regarding the content's validity. By using these platforms, you acknowledge and agree that you are solely responsible for your own investment decisions and actions. Fraywire, Breaking Metrics, and Glideslope AI shall not be held liable for any losses or damages resulting from the use of the information provided.

Get Connected

Fraywire & Glideslope AI are Breaking Metrics productions.
Contact the developer for advertising opportunities, questions, and more at roy@rmahd.com

○ Subscribe
○ Fraywire+
○ Glideslope AI
○ Blog
○ RMAHD
○ Merch!

Pulse AI Analysis

Related Insights

More Like This

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Pump.fun expands with Padre acquisition as memecoin market cools

OpenAI buys Sky, an AI interface for Mac

Fireblocks acquires Dynamic to expand enterprise wallet infrastructure

Crypto execs meet with senators to push forward market structure legislation: CNBC Crypto World

Buildots acquires workforce and safety management platform